Johnson & Johnson Says FDA Approved Monthly Dosing of Rybrevant Faspro for EGFR-Mutated Lung Cancer
MT Newswires Live
Yesterday
Johnson & Johnson (JNJ) said Tuesday that the US Food and Drug Administration has approved a simplified once-monthly dosing schedule for Rybrevant Faspro in combination with Lazcluze for first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The new schedule provides outcomes consistent with the previously approved bi-weekly subcutaneous regimen, the company said. Patients may transition to monthly dosing as early as Week 5, it added.
Rybrevant was recently approved as a subcutaneous formulation, reducing administration time from hours to minutes compared with intravenous delivery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.